Cargando…

Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies

The dynamic interplay between virus and host plays out across many interacting surfaces as virus and host evolve continually in response to one another. In particular, epitope-paratope interactions (EPIs) between viral antigen and host antibodies drive much of this evolutionary race. In this review,...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Nathaniel L., Raman, Rahul, Clark, Thomas, Sasisekharan, Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247215/
https://www.ncbi.nlm.nih.gov/pubmed/35784339
http://dx.doi.org/10.3389/fimmu.2022.904609
_version_ 1784739104691322880
author Miller, Nathaniel L.
Raman, Rahul
Clark, Thomas
Sasisekharan, Ram
author_facet Miller, Nathaniel L.
Raman, Rahul
Clark, Thomas
Sasisekharan, Ram
author_sort Miller, Nathaniel L.
collection PubMed
description The dynamic interplay between virus and host plays out across many interacting surfaces as virus and host evolve continually in response to one another. In particular, epitope-paratope interactions (EPIs) between viral antigen and host antibodies drive much of this evolutionary race. In this review, we describe a series of recent studies examining aspects of epitope complexity that go beyond two interacting protein surfaces as EPIs are typically understood. To structure our discussion, we present a framework for understanding epitope complexity as a spectrum along a series of axes, focusing primarily on 1) epitope biochemical complexity (e.g., epitopes involving N-glycans) and 2) antigen conformational/dynamic complexity (e.g., epitopes with differential properties depending on antigen state or fold-axis). We highlight additional epitope complexity factors including epitope tertiary/quaternary structure, which contribute to epistatic relationships between epitope residues within- or adjacent-to a given epitope, as well as epitope overlap resulting from polyclonal antibody responses, which is relevant when assessing antigenic pressure against a given epitope. Finally, we discuss how these different forms of epitope complexity can limit EPI analyses and therapeutic antibody development, as well as recent efforts to overcome these limitations.
format Online
Article
Text
id pubmed-9247215
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92472152022-07-02 Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies Miller, Nathaniel L. Raman, Rahul Clark, Thomas Sasisekharan, Ram Front Immunol Immunology The dynamic interplay between virus and host plays out across many interacting surfaces as virus and host evolve continually in response to one another. In particular, epitope-paratope interactions (EPIs) between viral antigen and host antibodies drive much of this evolutionary race. In this review, we describe a series of recent studies examining aspects of epitope complexity that go beyond two interacting protein surfaces as EPIs are typically understood. To structure our discussion, we present a framework for understanding epitope complexity as a spectrum along a series of axes, focusing primarily on 1) epitope biochemical complexity (e.g., epitopes involving N-glycans) and 2) antigen conformational/dynamic complexity (e.g., epitopes with differential properties depending on antigen state or fold-axis). We highlight additional epitope complexity factors including epitope tertiary/quaternary structure, which contribute to epistatic relationships between epitope residues within- or adjacent-to a given epitope, as well as epitope overlap resulting from polyclonal antibody responses, which is relevant when assessing antigenic pressure against a given epitope. Finally, we discuss how these different forms of epitope complexity can limit EPI analyses and therapeutic antibody development, as well as recent efforts to overcome these limitations. Frontiers Media S.A. 2022-06-17 /pmc/articles/PMC9247215/ /pubmed/35784339 http://dx.doi.org/10.3389/fimmu.2022.904609 Text en Copyright © 2022 Miller, Raman, Clark and Sasisekharan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Miller, Nathaniel L.
Raman, Rahul
Clark, Thomas
Sasisekharan, Ram
Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
title Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
title_full Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
title_fullStr Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
title_full_unstemmed Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
title_short Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
title_sort complexity of viral epitope surfaces as evasive targets for vaccines and therapeutic antibodies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247215/
https://www.ncbi.nlm.nih.gov/pubmed/35784339
http://dx.doi.org/10.3389/fimmu.2022.904609
work_keys_str_mv AT millernathaniell complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies
AT ramanrahul complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies
AT clarkthomas complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies
AT sasisekharanram complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies